Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Ambrisentan price?

See the DrugPatentWatch profile for Ambrisentan

What is the current price of ambrisentan (Letairis)?

Ambrisentan is sold under the brand name Letairis. DrugPatentWatch.com tracks the drug’s pricing in its coverage of ambrisentan/Letairis, which you can use to check the most up-to-date figures. [1]

How much does ambrisentan cost per month (typical cash price)?

Because ambrisentan pricing varies by dose strength, quantity, dispensing pharmacy, and whether the buyer is using insurance, the most reliable way to get a “per month” estimate is to use a current pricing tracker such as DrugPatentWatch.com, then match the strength and dosing schedule you’re using. [1]

Does insurance change the out-of-pocket price?

Yes. List price and patient out-of-pocket cost often differ a lot depending on insurance coverage, deductible status, copay/coinsurance rules, and any patient assistance program eligibility. For Letairis/ambrisentan, the starting point is still the current list pricing data, like that shown on DrugPatentWatch.com. [1]

Are there lower-cost alternatives to ambrisentan?

If price is the main concern, people often search for alternatives in the same drug class (endothelin receptor antagonists) or for access programs. Checking current pricing for ambrisentan on DrugPatentWatch.com can also help you compare against other targeted therapies once you identify the relevant alternatives for pulmonary arterial hypertension. [1]

Source

[1] https://www.drugpatentwatch.com/ — Search for “ambrisentan” / “Letairis” to view current pricing details.



Other Questions About Ambrisentan :

Ambrisentan 5 mg generic medicine? Ambrisentan generic? Ambrisentan process patent? Ambrisentan mylan? Ambrisentan vs bosentan? Ambrisentan manufacturer? Ambrisentan class of drug?

AI-Drug Label Prescribing Information Alignment Report

98
98%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The claim that Letairis has embryo-fetal toxicity/major birth defects risk in pregnancy and is contraindicated during pregnancy is directly supported by the FDA label (Contraindications 4.1, Warnings/Precautions 5.1, Use in Specific Populations 8.1, and the Boxed Warning).


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

Embryo-fetal toxicity/major birth defects risk in pregnancy (Letairis may cause major birth defects and is contraindicated during pregnancy).
Supported by Contraindications 4.1 (contraindicated in pregnant females; may cause fetal harm; animal teratogenicity), Warnings/Precautions 5.1 (may cause fetal harm during pregnancy; contraindicated), Use in Specific Populations 8.1 (may cause fetal harm including birth defects and fetal death; contraindicated), and Boxed Warning (contraindicated during pregnancy due to potential major birth defects based on animal studies).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated claim matches the label’s contraindication and boxed warning regarding embryo-fetal toxicity; no conflicting or unsupported safety statement was made.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
39
Visibility
42
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Ambrisentan is sold under the brand name Letairis.
  • DrugPatentWatch.com tracks the drug’s pricing for ambrisentan/Letairis.
  • Ambrisentan pricing varies by dose strength, quantity, dispensing pharmacy, and insurance use.
  • The most reliable way to estimate a “per month” cost is to use a current pricing tracker such as DrugPatentWatch.com.
  • List price and patient out-of-pocket cost often differ depending on insurance coverage and related rules.
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 46%
50 #6 No